In the Phase 1 NCT05168423 trial, patients with recurrent HER2-positive GBM treated with HER2-CAR virus-specific T cells showed an mOS of 11.1 months from infusion and 24.5 months from initial diagnosis [219]. This evidence concerns the gene ERBB2 and glioblastoma.